A rapid infusion protocol is safe for total dose iron polymaltose: Time for change

Internal Medicine Journal

Volumn 41, Issue 7, 2011, Pages 548-554

  Garg, M ^a   Morrison, G ^a   Friedman, A ^b   Lau, A ^c   Lau, D ^c   Gibson, P R ^a,d  

^a Eastern Health ^*  (Australia)

^b FRANKSTON HOSPITAL   (Australia)

^c EASTERN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Iron deficiency; Iron infusion; Iron polymaltose; Rapid iron infusion

Indexed keywords

CORTICOSTEROID; IRON POLYMALTOSE; PARACETAMOL;

ADULT; AGED; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CHEST TIGHTNESS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; DYSPNEA; ENTERITIS; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPOTENSION; INDIGESTION; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; THORAX PAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; CLINICAL PROTOCOLS; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 79960453840     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02356.x     Document Type: Article

References (26)

1. Looker AC, Dallman PR, Carroll MD. Prevalence of iron deficiency in the United States. JAMA 1997; 277: 973-6.
2. Bruner AB, Joffe A, Duggan AK. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996; 348: 992-6.
3. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007; 85: 778-87.
4. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. BSG Guidel Gastroenterol 2005 [cited 2010 Jan 26]. Available from URL:
5. Hershko C, Hoffbrand AV, Keret D. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 2005; 90: 585-95.
6. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
7. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24: 1507-23.
8. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-6.
9. al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T etal. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 69: 121-4.
10. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186: 518-22.
11. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106: 1335-40.
12. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Rana J etal. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
13. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.
14. Pinter T, Mossman T, Suto J, Vansteenkiste J. Effects of intravenous (IV) iron supplementation on responses to every-3-week (Q3W) darbepoetin alfa (DA) by baseline hemoglobin in patients (pts) with chemotherapy-induced anemia (CIA) [abstract]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings. 2007; 25 (Suppl 18): 9106.
15. Cuenca J, Garcia-Erce JA, Martinez AA, Solvano VM, Molina J, Munoz M. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005; 125: 342-7.
16. Garcia-Erce JA, Cuenca J, Munoz M. Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery. Transfus Med 2006; 16: 335-41.
17. Munoz M, Campos A, Garcia-Erce JA. Intravenous iron in colorectal surgery. Semin Hematol 2006; 43(Suppl 6): S36-8.
18. Newnam E, Ahmad I, Thornton A, Gibson PR. Safety of iron polymaltose given as a total dose iron infusion. Intern Med J 2006; 36: 672-4.
19. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82.
20. Haines ML, Gibson PR. Delayed reactions to total dose intravenous iron polymaltose. Intern Med J 2009; 39: 252-5.
21. Morris N (ed). Australian Injectable Drugs Handbook, 3rd edn. Melbourne:Society of Hospital Pharmacists; 2005; [cited 2009 Mar 20]. Available from URL:
22. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267-78.
23. Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008; 101: 67-73.
24. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Gasche C etal. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-92.
25. Manoharan A, Ramakrishna R, Pereira B. Delayed adverse reactions to total-dose intravenous iron polymaltose. Intern Med J 2009; 39: 857.
26. Ahmad I, Gibson PR. Management of iron deficiency in patients admitted to hospital: time for a rethink of treatment principles. Intern Med J 2006; 36: 347-54.